Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell Corporation (Nasdaq: ICCC) is an animal health company that develops, manufactures and markets scientifically proven and practical products to improve the health and productivity of dairy and beef cattle. News about ImmuCell often centers on sales performance for its First Defense® product line, strategic decisions regarding its Re-Tain® mastitis treatment candidate, and updates on manufacturing capacity and financing.
Investors following ICCC news can expect regular preliminary, unaudited product sales updates shortly after quarter-end, followed by detailed unaudited financial results releases. These announcements typically include commentary on product sales trends for First Defense®, including Tri-Shield® and Dual-Force® variants, domestic and international sales mix, gross margin performance, and the impact of prior production backlogs and inventory rebuilding.
Company news also covers strategic shifts, such as ImmuCell’s decision to focus resources on expanding the First Defense® franchise after receiving an FDA Incomplete Letter for the Re-Tain® New Animal Drug Application. Releases describe plans to increase the First Defense® sales force, expand manufacturing capacity, repurpose assets, and complete investigational Re-Tain® studies to support potential licensing or partnership opportunities.
Additional ICCC news items include leadership changes, such as the selection and onboarding of a new President and CEO, bank debt refinancing transactions, extensions of credit facilities, and details of conference calls with investors. For readers tracking ICCC, this news feed provides a centralized view of operational updates, product development milestones, capital structure developments and management commentary related to ImmuCell’s cattle health business.
ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited product sales for Q3 2025 and comparable periods. Q3 2025 sales were $5.5 million versus $6.0 million in Q3 2024. Year-to-date trends show $20.0 million for nine months and a trailing twelve-month total of $27.8 million, up from $23.8 million a year earlier.
Management attributes higher prior-period volume to distributor inventory rebuilds, warned of a second-half 2025 sales softening, noted a Non‑Administrative NADA submission in early January 2025, and began investigational use of Re‑Tain through year-end 2025 (not expected to generate revenue).
ImmuCell Corporation (Nasdaq: ICCC) has announced the appointment of Olivier te Boekhorst as its new President and CEO, effective November 1, 2025. Te Boekhorst, currently an Operating Partner at ARCHIMED and Chair of SeqCenter's Board, brings extensive industry experience from his 18-year tenure at IDEXX Laboratories, where he led significant growth initiatives in livestock diagnostics.
The transition includes current President and CEO Michael F. Brigham serving as Special Advisor for at least two months, while maintaining his Board position. Te Boekhorst's compensation package includes two stock option grants - an initial 76,673 shares at $5.90 per share and a subsequent grant of up to 85,000 shares, both vesting over three years.
ImmuCell Corporation (Nasdaq: ICCC) reported strong financial results for Q2 2025, with product sales increasing 18% to $6.4 million compared to Q2 2024. The company achieved significant improvements in profitability, posting net income of $502,000 ($0.06 per share) in Q2 2025, compared to a net loss of $1.5 million in Q2 2024.
Key financial metrics include gross margin improvement to 44% in Q2 2025 (up from 22% in Q2 2024), and cash position strengthening to $6.0 million as of June 30, 2025. The company has eliminated its order backlog and is building inventory for the peak selling season. Regarding Re-Tain®, ImmuCell has initiated Investigational Product use while reducing development expenses and exploring strategic options.
The company's stockholders' equity increased to $29.9 million, and Adjusted EBITDA improved to $1.4 million for the quarter.ImmuCell Corporation (Nasdaq: ICCC) has successfully refinanced its bank debt with Maine Community Bank (MCB). The company secured a new $2.33 million loan at 6.5% interest, which was used to pay off two existing loans: a $1.53 million MCB loan at 7% and a $768,209 FAME loan at 8%.
The refinancing eliminates approximately $1.95 million in balloon payments due in Q3 2026, extending the amortization schedule through Q3 2030. This move strengthens ImmuCell's financial position while maintaining its relationship with MCB. The company, which develops and manufactures health products for dairy and beef cattle, will discuss its Q2 2025 financial results in an upcoming conference call on August 15, 2025.
ImmuCell Corporation (Nasdaq: ICCC), an animal health company focused on dairy and beef cattle products, will announce its Q2 2025 financial results after market close on August 14, 2025. The company will host a conference call on August 15, 2025, at 9:00 AM ET to discuss the results.
ImmuCell manufactures First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal restrictions.
ImmuCell Corporation (Nasdaq: ICCC) reported strong preliminary Q2 2025 sales results, with total sales reaching $6.4 million, an 18% increase from Q2 2024. The company has successfully increased its production capacity to over $30 million per year and reduced its order backlog to under $100,000, down significantly from $3.4 million in May 2025.
The company is now evaluating additional investments to increase capacity by 33% to approximately $40 million to meet potential North American market demand. ImmuCell is also initiating Investigational Product use of Re-Tain® in H2 2025 to test market acceptance, following its Non-Administrative New Animal Drug Application submission in January 2025.
Twelve-month sales through June 2025 grew 22% to $28.3 million, demonstrating sustained growth across all reported periods. The company has transitioned from managing product allocations to pursuing new business opportunities now that distribution inventories have been rebuilt.
ImmuCell Corporation (Nasdaq: ICCC) has initiated a CEO succession planning process as current President and CEO Michael F. Brigham announces his intention to retire from full-time work by early 2026. Brigham, who joined ImmuCell in 1989 and has served as CEO since 2000, will turn 65 this fall.
The Board of Directors has already begun the search process, aiming to identify a new leader by year-end 2025. Brigham's financial responsibilities have been transferred to newly hired CFO Timothy C. Fiori. Brigham plans to remain with the company until a successor is found and will continue serving on the Board of Directors through his term ending in June 2026, with potential extended service subject to stockholder approval.
ImmuCell Corporation (NASDAQ: ICCC) has announced it will release its unaudited financial results for Q1 2025 after market close on May 14, 2025. The company will host a conference call on May 15, 2025, at 9:00 AM ET to discuss the results. The company maintains its preliminary sales results disclosed on April 8, 2025, with no anticipated changes. The Q1 2025 Form 10-Q filing is expected on May 14, 2025.
ImmuCell, focused on dairy and beef cattle health products, manufactures First Defense® for newborn calf immunity and is developing Re-Tain® for subclinical mastitis treatment in dairy cows. An updated Corporate Presentation will be available on the company's website after market close on May 14.